

What are the choices after metformin ?

Yale JF December 2015

| | SUs | DPP-4 Inhibitors | GLP-1R Agonists | SGLT2 Inhibitors | TZDs | Insulin |
|---------------------------|-------------------------|---|---|---|---------------|--------------------|
| A1c | -0.8 | -0.7 | -1.0 | -0.9 | -0.8 | -0.9 |
| BP | 0 | 0 | -4 | -4 | -7 | 0 |
| Weight | +2.2 | +0.2 | -1.7 | -1.7 | +2.5 | +1.4 |
| Hypos | YES | NO | NO | NO | NO | YES |
| Other Side Effects | Rare | Rare | Nausea, Bloating | Hypotension, Genital mycotic infections | Edema | Rare |
| CV Safety | Glyburide deleterious ? | Neutral for alogliptin, sitagliptin & saxagliptin (Small rise in hospitalizations for CHF with saxagliptin) | Neutral for lixisenatide. Ongoing trials for the others | Benefits demonstrated for empagliflozin Ongoing trials for the others | CHF x 2 | Neutral (Glargine) |
| | Gliclazide neutral | | | | | |
| Other | | Pancreatitis ? | Pancreatitis? | Ketoacidosis? | Fractures x 2 | |
| Experience | 1966 | 2006 | 2005 | 2013 | 2001 | 1921 |
| Route | ORAL | ORAL | INJECTION | ORAL | ORAL | INJECTION |
| Cost | \$ | \$\$\$ | \$\$\$\$\$ | \$\$\$ | \$\$\$ | \$\$ |